Search PubMed⌕ Search

Biomedical subjects

H Kim

Publications and source records attributed to H Kim.

At least 1,045 records · Page 58Linked to original sources
PubMed1985

Epidermal growth factor in mouse ocular tissue: effects of thyroxine and exogenous epidermal growth factor.

Using a specific and sensitive epidermal growth factor (EGF) radioimmunoassay, we identified radioimmunoassayable EGF both in developing and adult mouse ocular tissues. In neonatal animals ocular EGF concentrations increase during the first 4-9 days and then decline between 9 and 15 days. Thyroxine (T4) administration (0.4 micrograms/g body weight/day from day 0) increased local EGF concentrations in eye and skin of 7-day-old neonatal mouse pups. However, this treatment did not affect submandibular gland EGF concentrations during the 1st wk of life. Both EGF and T4 are known to accelerate eye opening in the neonatal mouse. Exogenous EGF administration (2 micrograms/g body weight/day) during the first 8 days of life elicited precocious eyelid opening as expected but did not alter the serum T4 concentration, suggesting that EGF does not mediate eye opening by T4 dependent mechanism(s). Tissue EGF measurements revealed that the exogenous EGF was localized in skin and eye; however, other tissues including lung, liver, heart and submandibular gland also contained exogenous EGF. Kidney-EGF concentrations did not rise while brain-EGF levels were significantly decreased after exogenous EGF, suggesting that different EGF uptake and regulatory mechanism(s) exist in different tissues during the neonatal period. T4 administration (0.4 micrograms/g body weight/day) for 10 days to adult mice also increased ocular-EGF concentrations. However, this increase was abolished by sialoadenectomy, suggesting in contrast to the newborn, that submandibular gland is an important source of ocular-EGF in adult mice. These studies indicate that ocular EGF in the mouse is thyroxine responsive only during the neonatal period.

Animals↗
PubMed1985

Computer imaging and analysis of dopamine (D2) and serotonin (S2) binding sites in rat basal ganglia or neocortex labeled by [3H]spiroperidol.

The equilibrium properties, pharmacological specificity and regional distribution of serotonin (S2) and dopamine (D2) binding sites in coronal or horizontal rat brain sections labeled by [3H] spiroperidol were investigated by computer analysis of digitized autoradiographs. Domperidone or (+)-butaclamol displaced [3H] spiroperidol from the anterior caudate-putamen, nucleus accumbens, olfactory tubercle, claustrum, layer 5A of motor cortex and layer 1 of the anterior cingulate cortex (IC50 = 2-80 nM). Equilibrium saturation analysis of the (+)-butaclamol-displaced binding of [3H]spiroperidol revealed higher binding affinities in the anterior caudate-putamen, nucleus accumbens and olfactory tubercle (Kd = 0.16-0.32 nM) than in the claustrum or layer 5A of motor cortex (Kd = 1.5-1.9 nM). The [3H]spiroperidol binding displaced by (+)-butaclamol was resolved into a dopaminergic (D2) component, displaced by 100 microM 2-amino-6,7-dihydroxytetrahydronapthalene or 10 microM (-)-sulpiride and a serotonergic (S2) component, displaced by 40 nM ketanserin or 100 nM methysergide. Methysergide or ketanserin displaced [3H]spiroperidol only from the caudal (peripallidal) caudate-putamen, claustrum or layer 5A of motor cortex (IC50 = 2-14 nM), whereas the D2 agonist 2-amino-6,7-dihydroxytetrahydronapthalene displaced [3H]spiroperidol from the caudate-putamen but not from cortex. The competition curve for 2-amino-6,7-dihydroxytetrahydronapthalene displacement of [3H]spiroperidol binding to D2 sites in the caudate-putamen was markedly biphasic and shifted to the right by the GTP analog, guanylimidodiphosphate. The D2 antagonist (+/-)- or (-)-sulpiride also displaced [3H]spiroperidol from the nucleus accumbens and olfactory tubercle as well as from the caudate-putamen (IC50 values = 0.14 microM). In contrast, the butyrophenone derivative, spirodecanone, displaced with equal potency all [3H]spiroperidol from each of the six brain regions. Neither the alpha-1 receptor ligand prazosin nor the excitatory amino acid receptor ligands l-aspartate, l-glutamate or dl-homocysteic acid displaced [3H]spiroperidol from any brain area. A 5-fold rostral-to-caudal gradient of decreasing S2 concentration was observed in neocortical layer 1 of horizontal sections. In the caudate-putamen, D2 density decreased by 30% rostrocaudally, whereas S2 sites were located mostly in the peripallidal caudate-putamen. The rostral-to-caudal gradients of D2 or S2 sites in the caudate-putamen correspond remarkably well with previously reported caudate-putamen concentration gradients for dopamine or serotonin, respectively.

Animals↗
PubMed1984

Acquisition of submandibular gland nerve growth factor (SMG-NGF) responsiveness to thyroxine administration in neonatal mice.

The growth of the submandibular gland (SMG) was studied in newborn mice from birth to 15 days of age. Progressive changes in wet weight were observed to accompany changes in biochemical constituents such as RNA, protein, and lipid. Thyroxine (T4) administration from days 0-6 produced changes in SMG growth and SMG accumulation of RNA, protein, and lipid components relative to control pups treated with a similar volume of vehicle. This hormone regimen produced no measurable changes in SMG nerve growth factor (SMG-NGF) concentration. T4 responsiveness also was studied from days 0-15. Three patterns of T4 injection (from days 0-6, 7-14, and 0-14) were found to elicit a differential response in the three biochemical constituents measured, but treatment from days 7-14 and 0-14 elicited precocious increments in SMG-NGF concentrations on day 15. The effect of T4 injection from birth was more effective in augmenting SMG-NGF concentration than hormone treatment initiated from days 7-14. A persistent T4 effect on SMG-NGF also was observed on day 21 following hormone treatment from days 7-14 or 0-14. In summary, the acquisition of SMG-NGF responsiveness to T4 appears to develop during the neonatal period. The administration of T4 during this period also precociously stimulates the mechanisms that govern the normal ontogeny of SMG-NGF at the time of weaning.

Age Factors↗
PubMed1984

Subcapsular urinoma: unusual form of "page kidney" in newborn.

The first case of renal hypertension resulting from a urinoma in a kidney secondary to vesicoureteral reflux from posterior urethral valves in a newborn is presented. High-pressure reflux resulted in formation of a subcapsular urinoma. Removal of the nonfunctioning "Page kidney" cured the persistent hypertension.

Humans↗
PubMed1984

The value of urinary fibrin/fibrinogen degradation products as tumor markers in urothelial carcinoma.

Urinary fibrin/fibrinogen degradation products as biological tumor markers in urothelial carcinoma have been studied and compared to urinary cytology. In 93 per cent of the patients with urothelial carcinoma urinary fibrin/fibrinogen degradation product levels were elevated significantly. There was excellent correlation when the urinary cytology and urinary fibrin/fibrinogen degradation product results were compared together to cystoscopic findings.

Carcinoma, Transitional Cell↗
PubMed1984

Heterogeneity of microtubule-associated protein 2 during rat brain development.

The electrophoretic pattern of the large microtubule-associated protein, MAP2, changes during rat brain development. Immunoblots of NaDodSO4 extracts obtained from the cerebral cortex, cerebellum, and thalamus at 10-15 days after birth reveal only a single electrophoretic species when probed with any of three MAP2 monoclonal antibodies. By contrast, adult MAP2 contains two immunoreactive species, MAP2a and MAP2b. The single band of MAP2 from immature brain electrophoretically comigrates with adult MAP2b. Between postnatal days 17 and 18, immature MAP2 simultaneously resolves into two species in both the cerebellum and cerebral cortex. Immunoblots of NaDodSO4 extracts from spinal cord demonstrate the adult complement of MAP2 by day 10, indicating that MAP2 does not change coordinately throughout the entire central nervous system. In vitro cAMP-dependent phosphorylation of immature MAP2 causes a band split reminiscent of that seen during brain development in vivo. The possibility that the developmentally regulated changes observed in MAP2 during brain maturation are due to timed phosphorylation events is discussed.

Aging↗
PubMed1984

Human ectopic fascioliasis in the cecum.

A case of ectopic human Fasciola spp. infection in the cecal wall is reported. The patient, a 27-year-old Korean woman, resident in Seoul, Korea, presented with nausea, vomiting, and epigastric tenderness. One week later a palpable mass was discovered in the right iliac fossa. A clinical diagnosis of a carcinoma of the colon was made and the patient underwent a cecal resection. The mass proved to be an inflammatory reaction containing numerous tracts made by the migrating fluke, Fasciola sp.

Adult↗
PubMed1984

A study on the mesothelial cell kinetics in pleural effusions by DNA cytophotometry and autoradiography with tritiated thymidine.

On 34 samples of pleural fluid a cell kinetic study of mesothelial cells was carried out by Feulgen-DNA cytophotometry and the autoradiographic estimation of 3H-thymidine uptake. The generation time of mesothelial cells in malignant effusions was found to be shorter than in non-malignant ones, thought he cellular activity for both effusions was essentially the same. Furthermore, with the development of complicating pleuritis from the early stage to the fibrino-fibrous stage, the appearance rate of 3H-thymidine labeled and activated mesothelial cells in the DNA synthetic phase changed quite differently in both effusions. The differences were thought to be due to neoplastic invasion itself or inflammatory reactions to the neoplastic growth.

Adult↗
PubMed1984

High-pressure liquid chromatographic method for determination of Sch 28191 in biological fluids.

A high-pressure liquid chromatographic method has been developed for the measurement of N-D-ornithyl amphotericin B methyl ester (Sch 28191) in biological fluid. The method involves protein precipitation with methanol, followed by separation of the supernatant on a reverse-phase column and quantitation by absorbance at 405 nm. This technique resulted in a recovery of 97%. There was a good linear relationship between the peak height ratio and Sch 28191 concentrations ranging from 0.015 to 20 micrograms/ml. In addition, this method was specific for Sch 28191 since all of its analogs tested did not interfere with the assay. The method was reproducible with a lower limit of quantitation of 0.015 microgram/ml. Serum levels obtained from this method were in good agreement with those obtained from a microbiological assay only when drug concentrations were higher than 1.5 microgram/ml. The high-pressure liquid chromatographic method is useful in monitoring serum and urine drug levels in animals and should prove to be useful for pharmacokinetic studies of the drug with therapeutic doses in humans.

Amphotericin B↗
PubMed1984

Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys.

The pharmacokinetics of Sch 28191, the N-D-ornithyl methyl ester of amphotericin B, and amphotericin B were studied in mice, rats, dogs, and cynomolgus monkeys after an intravenous dose of 0.6 mg/kg was administered. The decline in the concentrations of Sch 28191 and amphotericin B in serum appeared to be biphasic in nature. The half-life at the distribution phase and the half-life at the elimination phase of Sch 28191 were similar to those of amphotericin B in all animals studied. The half-life at the distribution phase in serum was 0.9 to 1.5 h in all animals studied. The half-lives at the elimination phase in serum were 25 to 28 h in mice, 16 to 18 h in rats, 44 to 47 h in dogs, and 35 h in cynomolgus monkeys. The areas under the serum concentration-time curves of Sch 28191 were five- to eightfold larger than those of amphotericin B in rats, dogs, and cynomolgus monkeys but were only slightly larger than those of amphotericin B in mice. In dogs, the urinary excretion (over 9 days) of unchanged drug accounted for 23% of the Sch 28191 dose and 25% of the amphotericin B dose. The concentrations of Sch 28191 in serum were also studied after the intravenous administration of 0.3, 0.6, or 1.25 mg/kg to dogs. The serum concentration-time curves were parallel for these doses. There was a linear relationship between the areas under the concentration-time curves and the doses, indicating dose proportionality.

Amphotericin B↗
PubMed1984

Inflammatory epicardial reaction to processed bovine pericardium: case report.

Processed bovine pericardium is increasingly used as a pericardial substitute. It is allegedly nonreactive with epicardium, but adequate clinical data are lacking on this subject. A case report is presented wherein a dense epicardial reaction to processed bovine pericardium was found at reoperation. Histologic examination confirmed the presence of a severe inflammatory response.

Animals↗
PubMed1983

Angioimmunoblastic lymphadenopathy. Long-term follow-up study.

The clinical course of 41 previously reported patients with angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) on whom follow-up information has been obtained for five or more years is described. Of the 41 patients, 27 achieved a complete remission (CR). The durations of the CR ranged from two to 214 months, with a median of 48 months. Nine of these 27 complete responders are still alive and well without evidence of disease, whereas the remaining 18 patients have died of pneumonia, septicemia, immunoblastic lymphoma, or unrelated causes. These 27 patients had a significantly longer median survival (51 mos) than did the 14 patients who had partial or no response (9 mos) (P = 0.0006). Only two of these 14 patients who did not initially achieve a CR are alive (survivals, 66 months and 70 months). There was a trend suggesting that patients who received combination chemotherapy which included prednisone had a slightly longer survival than did the remaining patients (P = 0.087). Lymphocytopenia was evident in a higher proportion of dead patients than in those who remained alive (P = 0.089).

Follow-Up Studies↗